This scale was developed Dr. Malaz Boustani, a researcher at the
Regenstrief Institute and the Indiana University Center for Aging
Research, and her colleagues.
A drug was given a score of 1 if it had possible anticholinergic
effects based on lab tests but no evidence of clinically relevant
cognitive effects A drug was given a score of 2 or 3 if it had
established and clinically relevant anticholinergic effects.
Drugs not listed have a score of 0.
The idea is to add up the scores of the drugs a person is taking.
If the sum of the scores is 3 or more, then medications with
lower anticholinergic cognitive burden scores might be considered
to lower the overall anticholinergic cognitive burden.
To continue reading this article, you must login
Subscribe to Harvard Health Online for immediate access to health news and information from Harvard Medical School.